Inogen, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kevin R. Smith
- Full Time Employees
- 766
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 301 Coromar Drive Goleta CA United States of America 93117
- IPO Date
- Feb 14, 2014
- CIK
- 0001294133
- Website
- inogen.com
- Similar Companies
- Business
- Inogen, Inc. (Nasdaq: INGN) develops, manufactures, and markets innovative portable oxygen concentrators and respiratory therapy devices for patients with chronic respiratory conditions in the homecare setting; core products include the Inogen One series (G4, G5), Rove 6 with six pulse dose settings and up to 12.8 hours of battery life, and the recently initiated Simeox airway clearance device; the company sells directly to consumers, rents units domestically, and distributes business-to-business to home medical equipment providers, prescribers, and international partners. Founded in 2001 and headquartered in Goleta, California, Inogen operates globally with manufacturing in Texas and California using sourced components, generating majority revenue in the United States while serving Canada, Europe, Asia-Pacific, and Latin America through distributors and large gas companies. In early 2025, Inogen secured a $27.2 million strategic collaboration with Yuwell, including a 9.9% equity investment closing in Q1 to expand product portfolio, global reach, and innovation pipeline via respiratory product distribution; the company reports seven consecutive quarters of mid-single-digit revenue growth through Q3 2025, achieving positive adjusted EBITDA and initiating limited U.S. release of Simeox.
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
Inogen, Inc. (INGN) Q1 2026 Earnings Call Transcript
INGN Stock Dips on Q1 Earnings Miss, Sales Up Y/Y, Gross Margin Improves
Inogen (INGN) Reports Q1 Loss, Beats Revenue Estimates
Inogen Announces First Quarter 2026 Financial Results
Inogen (NASDAQ:INGN) Stock Price Passes Above 50 Day Moving Average – Here’s What Happened
Inogen to Report First Quarter 2026 Financial Results on May 7, 2026
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
Inogen (INGN) Surges 6.9%: Is This an Indication of Further Gains?
Inogen Announces the Appointment of Vafa Jamali to Board of Directors
Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth
Inogen (INGN) Up 6.8% Since Last Earnings Report: Can It Continue?
Inogen (NASDAQ:INGN) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?
Inogen Announces Participation in the KeyBanc Virtual Life Sciences & MedTech Investor Forum
Inogen Stock Dips Despite Q4 Earnings Beat, Revenues Up Y/Y
Inogen, Inc. (INGN) Q4 2025 Earnings Call Transcript
Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates
Inogen Announces Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Outlook